We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) (SIGNET)

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: November 1, 2010
Last Update Posted: October 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
ViiV Healthcare
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label efavirenz (EFV) 600 mg once daily. The background ART for all 3 arms will be chosen by the Investigators and will be either abacavir/lamivudine [ABC/3TC] or tenofovir/emtricitabine [TDF/FTC] fixed dose combination (FDC) tablets. Antiviral activity, safety, PK, and development of viral resistance will be evaluated.

Condition Intervention Phase
Infection, Human Immunodeficiency Virus Drug: GSK2248761 100 mg once daily Drug: GSK2248761 200 mg once daily Drug: Efavirenz 600 mg once daily Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 Administered With Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Resource links provided by NLM:

Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:
  • HIV-1 viral load [ Time Frame: Week 16 ]
  • Incidence of AEs [ Time Frame: Week 16 ]
  • Incidence of SAEs [ Time Frame: Week 16 ]

Secondary Outcome Measures:
  • Incidence of HIV Associated Conditions [ Time Frame: through Week 96 ]
  • Changes in Immunologic Function (CD4/CD8 cell counts) [ Time Frame: through Week 96 ]
  • Changes in Viral Genotype [ Time Frame: through Week 96 ]
  • Absolute Values and Changes Over Time in Laboratory Parameters [ Time Frame: through Week 96 ]
  • Study Discontinuation Due to Adverse Events [ Time Frame: through Week 96 ]
  • Changes in ECG [ Time Frame: through Week 96 ]
  • Plasma GSK2248761 PK parameters - Cmin [ Time Frame: through Week 24 ]
  • Effect of Plasma GSK2248761 Concentrations on Plasma HIV-1 RNA levels [ Time Frame: through Week 24 ]
  • Incidence of AEs [ Time Frame: through Week 96 ]
  • Incidence of SAEs [ Time Frame: through Week 96 ]
  • Plasma GSK2248761 PK parameters - Cmax [ Time Frame: through Week 24 ]
  • Effect of Plasma GSK228761 Concentrations on Adverse Events [ Time Frame: through Week 24 ]
  • Changes in Viral Phenotype [ Time Frame: through Week 96 ]

Enrollment: 23
Study Start Date: November 2010
Estimated Study Completion Date: June 2013
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK2248761 100 mg once daily
In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
Drug: GSK2248761 100 mg once daily
1x100 mg capsule plus matching placebo
Experimental: GSK2248761 200 mg once daily
In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
Drug: GSK2248761 200 mg once daily
2x100 mg capsules
Active Comparator: Efavirenz 600 mg once daily
In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
Drug: Efavirenz 600 mg once daily
1x600mg tablet

  Show Detailed Description


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infected adults greater than or equal to 18 years of age. A female is eligible to enter and participate in the study if she is (1) Non-childbearing potential, (2) Child-bearing potential, with a negative pregnancy test at screen and Day 1 and agrees to use protocol-specified methods of birth control while on study
  • HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to 1000 copies/mL
  • CD4+ cell count greater than or equal to 200 cells/mm3
  • Antiretroviral-naive

Exclusion Criteria:

  • Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the subject
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug or render the subject unable to take oral medication
  • Women who are currently breastfeeding
  • Any evidence of an active Centers for Disease and Prevention Control (CDC) Category C disease [CDC,1993], except cutaneous Kaposi's sarcoma not requiring systemic therapy
  • History of ongoing or clinically relevant hepatitis within the previous 6 months, including chronic hepatitis B virus (HBV) infection (HBsAg positive). Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; subjects who are anticipated to require such therapy during the randomized portion of the study must be excluded
  • History of liver cirrhosis with or without hepatitis viral co-infection
  • Ongoing or clinically relevant pancreatitis
  • History of the following cardiac diseases: myocardial infarction, congestive heart failure, documented hypertrophic cardiomyopathy, sustained ventricular tachycardia
  • Personal or known family history of prolonged QT syndrome
  • History or presence of allergy or intolerance to the study drugs or their components, or a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled
  • Evidence of viral resistance to any antiviral drug indicative of primary transmitted resistance in a screening or historical resistance test result
  • Any acute laboratory abnormality at screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an investigational compound. Any verified Grade 4 laboratory abnormality at screening would exclude a subject from study participation unless the Investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the Medical Monitor
  • Any of the following laboratory values at screening: (1) Creatinine clearance <50 mL/min via Cockroft-Gault method, (2) Alanine aminotransferase (ALT) greater than or equal to 5 times upper limits of normal (ULN). Subjects with ALT > 2x ULN but <5xULN may participate in the study, if in the opinion of the Investigator and GSK Medical Monitor the lab abnormality will not interfere with the study procedures or compromise subject safety, (3) Alanine aminotransferase (ALT) greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with >35% direct bilirubin)
  • Any clinically significant finding on screening ECG, specifically (a single repeat is allowed to determine eligibility): (1) Heart rate <45 and >100 beats per minute (bpm) (males); <50 and >100 bpm (females). Note: A heart rate from 100 to 110 bpm can be rechecked within 30 minutes to verify eligibility, (2) QRS duration > 120 msec, (3) QTc interval > 450 msec (4) Non-sustained (greater than or equal to 3 consecutive beats) or sustained ventricular tachycardia, (5) Sinus pauses > 2.5 seconds, (6) 2nd degree (Type II) or higher AV (Atrioventricular) block, (7) Evidence of WPW (Wolff- Parkinson-White) syndrome (ventricular preexcitation), (8) Pathologic Q waves (defined as Q wave > 40 msec OR depth >0.4 mV (9) Any other abnormality which in the opinion of the Investigator would interfere with the safety of the subject
  • Treatment with any of the following agents within 28 days prior to screening, or has an anticipated need for these agents during the study (1) Radiation therapy or cytotoxic chemotherapeutic agents, (2) Immunomodulators (such as systemic corticosteroids, interleukins, or interferons) Note: Subjects using short-term (<7 day) steroid tapers and inhaled corticosteroids are eligible for enrollment (3) Any non-protocol-specified agent with documented activity against HIV 1 in vitro
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to screening
  • Receipt of an experimental drug and/or vaccine within 28 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine, whichever is longer, prior to screening
  • Immunization within 28 days prior to first dose of IP
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01231555

GSK Investigational Site
Levallois Perret, France, 92300
GSK Investigational Site
Montpellier Cedex 5, France, 34295
GSK Investigational Site
Nice, France, 06202
GSK Investigational Site
Paris, France, 75018
GSK Investigational Site
Frankfurt, Hessen, Germany, 60311
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Berlin, Germany, 12157
GSK Investigational Site
Hamburg, Germany, 20146
GSK Investigational Site
Badalona, Spain, 08916
GSK Investigational Site
Barcelona, Spain, 08036
GSK Investigational Site
Marid, Spain, 28040
Sponsors and Collaborators
ViiV Healthcare
Study Director: GSK Clinical Trials ViiV Healthcare
  More Information

Responsible Party: ViiV Healthcare
ClinicalTrials.gov Identifier: NCT01231555     History of Changes
Other Study ID Numbers: 113404
First Submitted: October 14, 2010
First Posted: November 1, 2010
Last Update Posted: October 17, 2017
Last Verified: April 2012

Keywords provided by ViiV Healthcare:
Sexually Transmitted Disease
antiretroviral therapy (ART)-naive adults
Immunologic Deficiency Syndrome
Retroviridae Infections
Acquired ImmunoDeficiency Syndrome (AIDS)
HIV infection

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers